Jun Qian
Capital Medical University
9 Papers
17 Citations
Jun Qian is an academic researcher from Capital Medical University. The author has contributed to research in topics: Primary central nervous system lymphoma & Rituximab. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
Xuefei Sun,Jing Liu,Yaming Wang,Xueyan Bai,Yuedan Chen,Jun Qian,Hong Zhu,Fusheng Liu,Xiaoguang Qiu,Shengjun Sun,Nan Ji,Yuanbo Liu +11 more
TL;DR: High-dose methotrexate based chemotherapy with rituximab yields a higher complete remission rate and does not increase serious toxicities, and PFS benefits from the addition of ritUXimab.
Isolated primary intracranial myeloid sarcoma with neuromeningeal infiltration: A case report
TL;DR: A 27-year-old male presented with a paroxysmal headache, accompanied by nausea and vomiting, which had persisted for one year, and eyesight deterioration that had been apparent for five months, in November 2012, and was diagnosed with myeloid sarcoma.
Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases.
Jing Liu,Xue‑Fei Sun,Jun Qian,Xue‑Yan Bai,Hong Zhu,Qu Cui,Xiaoyan Li,Yue‑Dan Chen,Yaming Wang,Yuan‑Bo Liu +9 more
TL;DR: The results indicated that the R-MAD immunochemotherapy regimen is effective in PCNSL patients without serious toxicity and a prospective investigation with more patients should be administered in order to understand the more accurate effect of the regimen.
Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population.
Yuchen Wu,Yaming Wang,Xuefei Sun,Xueyan Bai,Jun Qian,Hong Zhu,Qu Cui,Ruixian Xing,Yuedan Chen,Qing Liu,Jiayuan Guo,Nan Ji,Shengjun Sun,Yuanbo Liu +13 more
TL;DR: The majority of parenchymal involvement occurred within the first year of systemic lymphoma, in which mostly cases presenting with multiple and supratentorial locations, unlike what was found in PCNSL.
Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study.
Yuchen Wu,Xuefei Sun,Xueyan Bai,Jun Qian,Hong Zhu,Qu Cui,Ruixian Xing,Yuedan Chen,Qing Liu,Wenyuan Lai,Junhong Li,Yaming Wang,Shengjun Sun,Nan Ji,Yuanbo Liu +14 more
- 02 Apr 2021
TL;DR: In this paper, the feasibility of an R-MIADD (rituximab, high-dose methotrexate, ifosfamide, cytarabine, liposomal formulation of doxorubicin, and dexamethasone) regimen for SCNSL patients was evaluated.